Lunenfeld-Tanenbaum Research Institute
Jenny Wang
600 University Avenue
Mount Sinai Hospital, Sinai Health
Toronto, ON M5G 1X5
https://nbcc.lunenfeld.ca/facilities/high-throughput-screening
RRID: RRID:SCR_025390
BioMek NXp NXp
Beckman Coulter Biomek NXp Robotic Liquid Handler is designed to handle every aspect of liquid handling, pipetting, dilution, dispensing and integration in to one compact unit that will let you add laboratory automation where you need it. This efficient robotic liquid handler is set with a Span-8 pipette model, 4 fixed tip heads and 4 disposables, with rotating gripper and 8 channel liquid level sensing for an efficient and hands-free workflow. This automated workstation has up to 12 deck positions, automated labware positioners, and labware stacking for on deck storage. The open-ended flexibility of this robotic handler helps keep your lab agile and adaptable to your needs. The Beckman Coulter Biomek NXp Automated Workstation has a dispensing volume of between 0.5 ?L - 5,000 ?L and supports labware from tubes to 1,536-well microplates with accurate intra-well pipetting. The Biomek NXP can integrate with third party devices, and is configurable to meet specific applications needs. This automated workstation is computer controlled through the Biomek software, a robust suite that compliments this efficient instrument with methods and capabilities for genomic, drug discovery & basic research workflows. The Biomek software guides users through set up and protocols, quickly and easily through an icon based interface, with data tracking and LIMS connectivity. [Product Link]
RRID:SCR_019720
EnVision® 2105 Multimode Plate Reader
The EnVision® 2105 is a multimode microplate reader that provides speed, ultra-high throughput, and maximum sensitivity across all detection technologies.The EnVision 2105 model provides higher sensitivity for time-resolved fluorescence (TRF) applications, and the Enhanced Security software option includes tools to facilitate 21 CFR Part 11 compliance for integration into regulated environments (GxP). [Product Link]
RRID:SCR_018038
Assay Development
Drug Discovery
ELISA
High Content Screening
Inhibitor Screening
OLINK Proteomics
SiRNA Screening (human, Genome Wide)
SiRNA Screening (mouse, Genome Wide)
Small Molecule Compound Screening
1.) Nantel S, Sheikh-Mohamed S, Chao GYC, Kurtesi A, Hu Q, Wood H, Colwill K, Li Z, Liu Y, Seifried L, Bourdin B, McGeer A, Hardy WR, Rojas OL, Al-Aubodah TA, Liu Z, Ostrowski MA, Brockman MA, Piccirillo CA, Quach C, Rini JM, Gingras AC, Decaluwe H, Gommerman JL (2024 Apr). Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity. Mucosal immunology, 17(2), 201-210. doi: 10.1016/j.mucimm.2024.01.004. ID: 38278415.
2.) Richard L, Nisenbaum R, Colwill K, Mishra S, Dayam RM, Liu M, Pedersen C, Gingras AC, Hwang SW (2024 Feb 2). Enhancing detection of SARS-CoV-2 re-infections using longitudinal sero-monitoring: demonstration of a methodology in a cohort of people experiencing homelessness in Toronto, Canada. BMC infectious diseases, 24(1), 125. . ID: 38302878.
3.) Enilama O, Yau K, Er L, Atiquzzaman M, Oliver MJ, Romney MG, Leis JA, Abe KT, Qi F, Colwill K, Gingras AC, Hladunewich MA, Levin A (2024). Humoral Response Following 3 Doses of mRNA COVID-19 Vaccines in Patients With Non-Dialysis-Dependent CKD: An Observational Study. Canadian journal of kidney health and disease, 11(), 20543581231224127. . ID: 38292817.
4.) Walmsley S, Nabipoor M, Lovblom LE, Ravindran R, Colwill K, McGeer A, Dayam RM, Manase D, Gingras AC, On Behalf Of The STOPCoV Team (2023 Dec 28). Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination. Vaccines, 12(1), . . ID: 38250849.
5.) Camirand Lemyre F, Honfo SH, Caya C, Cheng MP, Colwill K, Corsini R, Gingras AC, Jassem A, Krajden M, Márquez AC, Mazer BD, McLennan M, Renaud C, Yansouni CP, Papenburg J, Lewin A (2023 Dec). Two-phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID-19 serological assays as a proof of concept. Vox sanguinis, 118(12), 1069-1077. doi: 10.1111/vox.13545. ID: 37850270.
6.) Di Meo A, Ma L, Yau K, Abe KT, Colwill K, Gingras AC, Kozak R, Hladunewich MA, Yip PM (2023 Nov). Evaluation of commercial assays for the assessment of SARS-CoV-2 antibody response in hemodialysis patients. Clinical biochemistry, 121(), 110681. doi: 10.1016/j.clinbiochem.2023.110681. ID: 37913837.
7.) Matveev VA, Mihelic EZ, Benko E, Budylowski P, Grocott S, Lee T, Korosec CS, Colwill K, Stephenson H, Law R, Ward LA, Sheikh-Mohamed S, Mailhot G, Delgado-Brand M, Pasculescu A, Wang JH, Qi F, Tursun T, Kardava L, Chau S, Samaan P, Imran A, Copertino DC Jr, Chao G, Choi Y, Reinhard RJ, Kaul R, Heffernan JM, Jones RB, Chun TW, Moir S, Singer J, Gommerman J, Gingras AC, Kovacs C, Ostrowski M (2023 Oct 20). Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV. iScience, 26(10), 107915. . ID: 37790281.
8.) Yau K, Tam P, Chan CT, Hu Q, Qi F, Abe KT, Kurtesi A, Jiang Y, Estrada-Codecido J, Brown T, Liu L, Siwakoti A, Leis JA, Levin A, Oliver MJ, Colwill K, Gingras AC, Hladunewich MA (2023 Oct 17). BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients. Clinical journal of the American Society of Nephrology : CJASN, 19(1), 85-97. . ID: 37847518.
9.) Yau K, Kurtesi A, Qi F, Delgado-Brand M, Tursun TR, Hu Q, Dhruve M, Kandel C, Enilama O, Levin A, Jiang Y, Hardy WR, Yuen DA, Perl J, Chan CT, Leis JA, Oliver MJ, Colwill K, Gingras AC, Hladunewich MA (2023 Sep 27). Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease. Nature communications, 14(1), 6041. . ID: 37758707.
10.) Lin YJ, Evans DH, Robbins NF, Orjuela G, Abe KT, Rathod B, Colwill K, Gingras AC, Tuite A, Yi QL, O (2023 Aug 17). Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021. Microbiology spectrum, 11(4), e0525622. . ID: 37289096.
11.) Murphy TJ, Swail H, Jain J, Anderson M, Awadalla P, Behl L, Brown PE, Charlton CL, Colwill K, Drews SJ, Gingras AC, Hinshaw D, Jha P, Kanji JN, Kirsh VA, Lang ALS, Langlois MA, Lee S, Lewin A, O (2023 Aug 14). The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023. CMAJ : Canadian Medical Association journal = journal de l, 195(31), E1030-E1037. . ID: 37580072.
12.) Matveev VA, Mihelic EZ, Benko E, Budylowski P, Grocott S, Lee T, Korosec CS, Colwill K, Stephenson H, Law R, Ward LA, Sheikh-Mohamed S, Mailhot G, Delgado-Brand M, Pasculescu A, Wang JH, Qi F, Tursun T, Kardava L, Chau S, Samaan P, Imran A, Copertino DC Jr, Chao G, Choi Y, Reinhard RJ, Kaul R, Heffernan JM, Jones RB, Chun TW, Moir S, Singer J, Gommerman J, Gingras AC, Kovacs C, Ostrowski M (2023 Jun 15). Immunogenicity of COVID-19 vaccines and their effect on the HIV reservoir in older people with HIV. bioRxiv : the preprint server for biology, (), . . ID: 37502977.
13.) Kondratyev M, Pesic A, Ketela T, Stickle N, Beswick C, Shalev Z, Marastoni S, Samadian S, Dvorkin-Gheva A, Sayad A, Bashkurov M, Boasquevisque P, Datti A, Pugh TJ, Virtanen C, Moffat J, Grénman RA, Koritzinsky M, Wouters BG (2023 May 18). Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer. Communications biology, 6(1), 538. . ID: 37202533.
14.) Breznik JA, Rahim A, Kajaks T, Hagerman M, Bilaver L, Colwill K, Dayam RM, Gingras AC, Verschoor CP, McElhaney JE, Bramson JL, Bowdish DME, Costa AP (2023 May). Protection from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada. Journal of the American Medical Directors Association, 24(5), 753-758. . ID: 37001559.
15.) Walmsley SL, Szadkowski L, Wouters B, Clarke R, Colwill K, Rochon P, Brudno M, Ravindran R, Raboud J, McGeer A, Oza A, Graham C, Silva A, Manase D, Maksymowsky P, Parente L, Dayam RM, Simpson J, Pasculescu A, Gingras AC (2023 Apr 21). COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series. iScience, 26(4), 106506. . ID: 37073374.
16.) Richard L, Nisenbaum R, Brown M, Liu M, Pedersen C, Jenkinson JIR, Mishra S, Baral S, Colwill K, Gingras AC, McGeer A, Hwang SW (2023 Mar 1). Incidence of SARS-CoV-2 Infection Among People Experiencing Homelessness in Toronto, Canada. JAMA network open, 6(3), e232774. . ID: 36912833.
17.) Yau K, Enilama O, Levin A, Romney MG, Singer J, Blake P, Perl J, Leis JA, Kozak R, Tsui H, Bolotin S, Tran V, Chan CT, Tam P, Dhruve M, Kandel C, Estrada-Codecido J, Brown T, Siwakoti A, Abe KT, Hu Q, Colwill K, Gingras AC, Oliver MJ, Hladunewich MA (2023). Determining the Longitudinal Serologic Response to COVID-19 Vaccination in the Chronic Kidney Disease Population: A Clinical Research Protocol. Canadian journal of kidney health and disease, 10(), 20543581231160511. . ID: 36950028.
18.) Lin YJ, Evans DH, Robbins NF, Orjuela G, Hu Q, Samson R, Abe KT, Rathod B, Colwill K, Gingras AC, Tuite A, Yi QL, O (2022 Oct 26). Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses. Microbiology spectrum, 10(5), e0281122. . ID: 36125288.
19.) Cholette F, Fabia R, Harris A, Ellis H, Cachero K, Schroeder L, Mesa C, Lacap P, Arnold C, Galipeau Y, Langlois MA, Colwill K, Gingras AC, McGeer A, Giles E, Day J, Osiowy C, Durocher Y, Hankins C, Mazer B, Drebot M, Kim J (2022 Sep). Comparative performance data for multiplex SARS-CoV-2 serological assays from a large panel of dried blood spot specimens. Heliyon, 8(9), e10270. . ID: 36060461.
20.) Han H, Best AJ, Braunschweig U, Mikolajewicz N, Li JD, Roth J, Chowdhury F, Mantica F, Nabeel-Shah S, Parada G, Brown KR, O (2022 Aug 18). Systematic exploration of dynamic splicing networks reveals conserved multistage regulators of neurogenesis. Molecular cell, 82(16), 2982-2999.e14. . ID: 35914530.
The high-throughput screening facility of the Network Biology Collaborative Centre (NBCC) provides cutting-edge instrumentation and in-depth expertise for the automation of laboratory processes. Directed by Dr. Jeff Wrana, the facility has 2 automated screening platforms and accessory equipment to enable flexible and scalable in vitro and in vivo assays (including organoids).
Our full-service offerings include access to chemical and genome-wide siRNA libraries, assay development and implementation, and data analysis.
Applications include:
drug discovery and lead validation
ELISA-based assays for immune surveillance
protein biomarker discovery using OLINK proteomics technology
multiplexed barcode screening assays
